Finoriq research workspace
Alzamend Neuro, Inc. (ALZN) Historical Metrics
Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline. Review ALZN valuation ratios, fundamentals, and filing metrics on Finoriq.
Company Snapshot
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
- Company
- Alzamend Neuro, Inc. (ALZN)
- Ticker
- ALZN
- Market Cap
- $4.8M
- Latest Price
- $1.26
- Industry
- Biotech & Pharma
Alzamend Neuro, Inc. (ALZN) Current Valuation Metrics
Static valuation preview for Alzamend Neuro, Inc. (ALZN). Market data retrieved 2026-07-09. Filing currency USD.
| Metric | Value | Source |
|---|---|---|
| Earnings YieldLatest TTM net income divided by market cap. | -163.8% | Net Income | TTM Q3 2026 |
| Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap. | -138.6% | Operating Cash Flow | TTM Q3 2026 |
| Price / BookMarket cap divided by stockholders' equity. | 1.97x | Stockholders' Equity | Q3 2026 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.